BOSTON, MA / ACCESSWIRE / April 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® ...

To understand the role of 4-1BB in the progression of CIA, we induced CIA in DBA/1 mice and treated them intraperitoneally (i.p.) with agonistic anti-4-1BB or blocking anti-4-1BB ligand (anti-4-1BBL).

ABL Bio, a company specializing in bispecific antibodies, announced on September 26 that it has received a decision of patent grant for its 4-1BB monoclonal antibody and its applications in South ...

Swedish firm Alligator Bioscience and Seattle-based Aptevo Therapeutics have agreed to co-develop ALG.APV-527, a bispecific antibody for tumor-directed immunotherapy, which is based on Alligator’s ...

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "With Opamtistomig now receiving Fast Track Designation from the FDA—following Breakthrough Therapy Designation in China and Orphan ...

Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody ...

SHANGHAI--(BUSINESS WIRE)--Lvgen Biopharma, a biotech company focused on developing innovative immuno-oncology therapeutics, announces that it will present a Trials in Progress poster presentation at ...

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors. This is an ASCO Meeting Abstract from the ...

Conventionally, the first and second stimulation signals in vitro, simulating the process in vivo, are achieved using anti-CD3 antibody, anti-CD28 antibody, or CD3/CD28 magnetic beads, along with the ...